2894-68-0

Basic information

• Product Name: Diclazepam
• Synonyms: 2-chlorodiazepam;1-Methyl-7-chloro-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one;1-Methyl-7-chloro-5-(2-chlorophenyl)-1H-1,4-benzodiazepine-2(3H)-one;7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one;o-Chlorodiazepam;Ro 5-3448;DiclazepaM;2H-1,4-Benzodiazepin-2-one,7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1-Methyl-
• CAS NO: 2894-68-0
• Molecular Formula: C₁₆H₁₂Cl₂N₂O
• Molecular Weight: 319.19
• EINECS: 200-100-6
• Product Categories: research chemical;medical intermediate
• Mol File: 2894-68-0.mol
• Article Data: 4

Chemical Properties

• Melting Point: 217-219℃ (dichloromethane ethyl ether )
• Boiling Point: 524.6°Cat760mmHg
• Flash Point: 271.1°C
• Appearance: /
• Density: 1.35±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 4.23E-11mmHg at 25°C
• Refractive Index: 1.647
• PKA: 1.75±0.25(Predicted)
• CAS DataBase Reference: Diclazepam(CAS DataBase Reference)
• NIST Chemistry Reference: Diclazepam(2894-68-0)
• EPA Substance Registry System: Diclazepam(2894-68-0)

Safety Data

• Statements: 22
• Safety Statements: 22-24/25
• Hazardous Substances Data: 2894-68-0(Hazardous Substances Data)

Usage

Description

Diclazepam, also known as 2-chlorodiazepam and chlorodiazepam, is classed in the benzodiazepam family, and is therefore a diazepam analogue.It was first synthesized by Leo Sternbach and his team at Hoffman-La Roche in 1960, but it was not pursued as a pharmaceutical product.Diclazepam dosage, efficacy or safety in humans has never been formally studied. In animals, however, it is known to have very similar effects to flubromazepam and diazepam itself. Its effects include working as an anticonvulsant and anxiolytic, a sedative, a hypnotic, an amnesiac and as a skeletal muscle relaxant. It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Diclazepam has been assessed as having an elimination half-life of around 42 hours in most animals. In the body, it undergoes N-demethylation, resulting in the creation of delorazepam. The delorazepam can be detected in the subject’s urine for approximately six days. It also metabolises into lormetazepam (detectable for 19 days) and lorazepam (detectable for 11 days). This suggests that cytochrome P450 enzymes are also engaging in hydroxylation of the compound at the same time as the N-demethylation.

InChI:InChI=1/C16H12Cl2N2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3

Upstream product

• 5504-92-7 2-(2-bromo-acetylamino)-5,2'-dichloro-benzophenone 
• 2958-36-3 (2-amino-5-chloro-phenyl)-(2-chloro-phenyl)-methanone 
• 2894-67-9 delorazepam 
• 74-88-4 methyl iodide 

Downstream Products

• 54042-83-0 7-chloro-5-(2-chloro-phenyl)-3-(dimethylamino-methylene)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant articles and documents

Structure-Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin

High-throughput screening has shown that Retro-1 inhibits ricin and Shiga toxins by diminishing their intracellular trafficking via the retrograde route, from early endosomes to the Golgi apparatus. To improve the activity of Retro-1, a structure-activity relationship (SAR) study was undertaken and yielded an analogue with a roughly 70-fold better half-maximal effective concentration (EC50) against Shiga toxin cytotoxicity measured in a cell protein synthesis assay.

Method for inhibiting the proliferation of tumor cells

A method of inhibiting the proliferation of tumor cells is disclosed which comprises the treatment of such tumor cells with a benzodiazepine having a selective affinity to bind peripheral binding sites on the tumor cell in order to induce non-proliferation of said tumor cells.